CEO Pershing Edward Buys 1.3M Preferred Shares in Provectus Biopharma – A Bullish Signal for Investors
CEO Pershing Edward’s conversion of a $2.86‑price note into 1.3 M preferred shares at $0.06 common stock shows strong confidence in Provectus’s oncology pipeline and signals potential upside for risk‑tolerant investors.
- Provectus Biopharmaceuticals Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read